Products
Teicoplanin is commercially available as a drug for parenteral administration (Targocid, generics). It has been approved in many countries since 1990.
Structure and properties
Teicoplanin is a mixture of structurally similar and complex molecules isolated from.
Effects
Teicoplanin (ATC J01XA02) is mostly bactericidal and partially bacteriostatic against aerobic and anaerobic Gram-positive bacteria. The effects are based on inhibition of cell wall synthesis.
Indications
For the treatment of bacterial infectious diseases with susceptible pathogens. Teicoplanin is used against resistant Gram-positive pathogens, infections associated with penicilin or cephalosporin allergy, and pseudomembranous enterocolitis, among others.
Dosage
According to the SmPC. The drug is usually administered intravenously or intramuscularly. For the treatment of pseudomembranous enterocolitis, it is given perorally. When given orally, teicoplanin acts locally in the intestine and is not absorbed.
Contraindications
- Hypersensitivity
- The drug should not be injected into the subarachnoid space.
For complete precautions, see the drug label.
Interactions
Complete information on interactions with other drugs is not available.
Adverse effects
The most common possible adverse effects include skin flushing, rash, itching, pain, fever, and a transient increase in liver enzymes. Teicoplanin, like other glycopeptide antibiotics, can cause oto- and nephrotoxic side effects.